Glaxosmithkline Biologicals S.A. Sustainability Profile
GlaxoSmithKline Biologicals S.A., commonly referred to as GSK Biologicals, is a leading global player in the biopharmaceutical industry, headquartered in Belgium. Founded in 1995, the company has established itself as a pioneer in vaccine development, focusing on innovative solutions to combat infectious diseases. With a strong operational presence across Europe, North America, and emerging markets, GSK Biologicals is dedicated to enhancing public health through its extensive portfolio of vaccines. The company’s core offerings include vaccines for diseases such as influenza, hepatitis, and meningitis, distinguished by their advanced research and development processes. GSK Biologicals has achieved notable milestones, including the introduction of several groundbreaking vaccines that have significantly impacted global health. As a subsidiary of GlaxoSmithKline plc, it continues to maintain a robust market position, recognised for its commitment to quality and innovation in the biopharmaceutical sector.
DitchCarbon Score
How does Glaxosmithkline Biologicals S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glaxosmithkline Biologicals S.A.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Glaxosmithkline Biologicals S.A., headquartered in Belgium (BE), currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of GSK plc, which may influence its climate commitments and initiatives. While specific reduction targets or achievements are not detailed, Glaxosmithkline Biologicals S.A. aligns its climate strategies with those of its parent company, GSK plc. This includes participation in various sustainability initiatives such as the Science Based Targets initiative (SBTi), CDP, RE100, and the Climate Pledge, all of which are cascaded from GSK plc. These initiatives aim to enhance transparency and accountability in reducing carbon emissions across their operations. As a part of GSK plc's broader climate strategy, Glaxosmithkline Biologicals S.A. is expected to contribute to the overarching goals of reducing greenhouse gas emissions and promoting sustainable practices within the pharmaceutical industry. However, specific metrics or targets for Glaxosmithkline Biologicals S.A. have not been disclosed at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 1,040,928,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 788,149,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 16,630,521,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
How Carbon Intensive is Glaxosmithkline Biologicals S.A.'s Industry?
How Carbon Intensive is Glaxosmithkline Biologicals S.A.'s Location?
Glaxosmithkline Biologicals S.A.'s Scope 3 Categories Breakdown
Glaxosmithkline Biologicals S.A.'s Scope 3 emissions, which decreased by 0% last year and decreased by approximately 46% since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Use of Sold Products" being the largest emissions source at 56% of Scope 3 emissions.
Top Scope 3 Categories
Glaxosmithkline Biologicals S.A.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Glaxosmithkline Biologicals S.A. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
